2021
DOI: 10.1111/nyas.14681
| View full text |Cite
|
Sign up to set email alerts
|

Abstract: For many years, it was believed that the aging process was inevitable and that age-related diseases could not be prevented or reversed. The geroscience hypothesis, however, posits that aging is, in fact, malleable and, by targeting the hallmarks of biological aging, it is indeed possible to alleviate age-related diseases and dysfunction and extend longevity. This field of geroscience thus aims to prevent the development of multiple disorders with age, thereby extending healthspan, with the reduction of morbidi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 18 publications
(9 citation statements)
references
References 119 publications
0
8
0
Order By: Relevance
“…Through conducting pilot trials across various age-related conditions and using different types of senolytic agents, the Geroscience Hypothesis can be tested in human patients. This hypothesis postulates that by targeting a fundamental aging process or a hallmark of biological aging, such as cellular senescence, multiple age-related pathologies can be remarkably delayed, alleviated or effectively prevented, as a group, instead of one-at-a-time [ 148 ]. By definition, the aim of developing senolytics is to target senescent cells, while the long-term goal is to restrain development of geriatric diseases, extend human healthspan, and reduce morbidity toward the end of life.…”
Section: Research Limitationsmentioning
confidence: 99%
“…Through conducting pilot trials across various age-related conditions and using different types of senolytic agents, the Geroscience Hypothesis can be tested in human patients. This hypothesis postulates that by targeting a fundamental aging process or a hallmark of biological aging, such as cellular senescence, multiple age-related pathologies can be remarkably delayed, alleviated or effectively prevented, as a group, instead of one-at-a-time [ 148 ]. By definition, the aim of developing senolytics is to target senescent cells, while the long-term goal is to restrain development of geriatric diseases, extend human healthspan, and reduce morbidity toward the end of life.…”
Section: Research Limitationsmentioning
confidence: 99%
“…The great benefit of drug repurposing was also highlighted by Nir Barzilai, Albert Einstein College of Medicine, USA, who studies the repurposing of FDA approved drugs such as metformin and canagliflozin [61]. As aging is not currently recognized as a disease by the FDA, drug repurposing is an invaluable tool [62]. Anne-Ulrike Trendelenburg, Novartis Institutes for Biomedical Research, USA, presented a roadmap on how to conduct preclinical testing of geroprotectors for easy clinical translation.…”
Section: Agingmentioning
confidence: 99%
“…Geroscience aims at understanding the basic mechanisms driving aging and using that knowledge to develop clinical interventions against multimorbidity at old age [75][76][77] . Because this multimorbidity is mechanistically anchored in basic mechanisms of aging, such interventions would then prevent, delay or cure multiple chronic age-related diseases simultaneously.…”
Section: Can We Succeed Where Gilgamesh Failed?mentioning
confidence: 99%